摘要
中国人口老龄化日益严重,骨质疏松症的发生率愈来愈高,其防治费用给患者家庭和社会经济造成了沉重的负担。随着国家分级诊疗制度建设的深入,各级医疗机构就诊人数越来越多,其中大部分对于骨质疏松症的认识程度较低。在此背景下,骨质疏松症初筛工具的应用显得尤为重要。亚洲人骨质疏松自我筛查工具(osteoporosis self-assessment tool for Asians,OSTA)是针对亚洲绝经后女性制定的一套工具,只参考年龄和体重两个因素。虽然在使用过程中仍存在一定的局限性,但具有操作简单方便,灵敏度相对较高的特点,特别是在缺乏检测手段的基层医疗机构中进行骨质疏松筛查应用方面前景广阔。本文将近年来利用OSTA在中国各级医疗机构进行骨质疏松筛查的相关研究进行综述,旨在探讨OSTA在此方面的适用性,以期为骨质疏松症的初筛、管理、分级诊疗等方面提供新视角。
Because of the increasingly aging population and higher incidence of osteoporosis in China,its prevention and treatment costs place a heavy burden on the patient’s family and socioeconomy.With the deepening of the construction of the national hierarchical diagnosis and treatment system,the number of patients in medical institutions at all levels is increasing,and most of them have a low understanding of osteoporosis.Under this background,the application of osteoporosis screening tool is particularly important.The osteoporosis self assessment tool for Asians(OSTA)is a set of tools for Asian postmenopausal women.It only refers to age and weight.Although there are still some limitations in the use,it has the characteristics of simple and convenient operation and relatively high sensitivity,Especially in the grass-roots medical institutions lacking detection means,there is a broad prospect in the application of osteoporosis screening.This paper reviews the relevant studies on osteoporosis screening using OSTA in medical institutions at all levels in China in recent years,in order to explore the applicability of OSTA in this regard,in order to provide a new perspective on the primary screening,management,graded diagnosis and treatment of osteoporosis in China.
作者
付赛
赵宇
王世浩
刘树华
张桂鑫
黄宏兴
万雷
FU Sai;ZHAO Yu;WANG Shihao;LIU Shuhua;ZHANG Guixin;HUANG Hongxing;WAN Lei(The Third Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China;The Third Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510375, China)
出处
《中国骨质疏松杂志》
CAS
CSCD
北大核心
2022年第7期1077-1081,共5页
Chinese Journal of Osteoporosis
基金
国家自然科学基金面上项目(81973886,82174395)
广州中医药大学“双一流”与高水平大学学科协同创新团队重点项目(2021XK21)。